Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells

Leukemia and Lymphoma

Volumn 56, Issue 8, 2015, Pages 2458-2459

  DArena, Giovanni ^a   Ruggieri, Vitalba ^a   Dauria, Fiorella ^a   La Rocca, Francesco ^a   Simeon, Vittorio ^a   Statuto, Teodora ^a   Caivano, Antonella ^a   Telesca, Donatella ^a   Del Vecchio, Luigi ^b   Musto, Pellegrino ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; LENALIDOMIDE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; CELL EXPANSION; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; FLOW CYTOMETRY; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; CELL MEMBRANE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CELL MEMBRANE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; THALIDOMIDE;

EID: 84943380476     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.999329     Document Type: Letter

References (9)

1. Kater AP, Tonino SH, Egle A, et al. How does lenalidomide target the chronic lymphocytic leukemia microenvironment? Blood 2014; 124: 2184-2189.
2. Giannopoulos K, Mertens D, Stilgenbauer S. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide. Expert Opin Pharmacother 2011; 12: 2857-2864.
3. Ramsay AG, Gribben JG. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immuno-modulatory drug. Haematologica 2009; 94: 1198-1202.
4. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010; 47: 115-123.
5. DArena G, Musto P, Cascavilla N, et al. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol 2000; 64: 275-281.
6. Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2013; 31: 584-591.
7. Lapalombella R, Yu B, Triantafillou G, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008; 112: 5180-5189.
8. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumor activity of rituximab in vivo. Br J Haematol 2007; 140: 36-45.
9. Gaidarova S, Mendy D, Heise C, et al. Lenalidomide induces capping of CD20 and cytoskeleton proteins to enhance rituximab immune recognition of malignant B-cells. Blood 2010; 116 (Suppl. 1): Abstract 2845.